Trinity Life Science’s Monica Martin De Bustamante analyzes the Medicare-negotiated prices of the first 10 drugs under the Inflation Reduction Act.
Trinity Life Science’s Monica Martin De Bustamante analyzes the Medicare-negotiated prices of the first 10 drugs under the Inflation Reduction Act.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
By clicking ‘Accept,’ you consent to the collection and sharing of data as described in our Privacy Policy.